Charlotte Robinson

DocwireNews

Critical Path Institute&nbsp;(C-Path)&nbsp;announced that its&nbsp;Polycystic Kidney Disease Outcomes Consortium&nbsp;has received a Broad Agency Announcement (BAA) contract focused on autosomal dominant tubulointerstitial kidney disease (ADTKD) from the US Food and Drug Administration (FDA).C-Path is an independent nonprofit whose mission is to lead collaborations that advance better treatments worldwide. The organization has established numerous international consortia, programs, and initiatives including more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations, and pharmaceutical and biotech companies.The BAA award will support C-Path&rsquo;s work in collaboration with the Wake Forest Rare Inherited Kidney Disease team and its ADTKD registry, to analyze clinical and laboratory data that will help assess prognosis in ADTKD and advance future drug development efforts and clinical trials.ADTKD is primarily caused by genetic mutations in the UMOD and MUC1 genes. Because it is rare and was only recently identified as a cause of kidney disease, little is known about factors that affect progression of kidney disease in ADTKD. Identification of the genetic causes of ADTKD has led to increased detection, and it is now estimated to be the third most common form of inherited kidney disease.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

C-Path Receives BAA Award From FDA to Support ADTKD Drug Development

Nephrology Times

C-Path's Polycystic Kidney Disease Outcomes Consortium received a Broad Agency Announcement contract from the FDA, which will support advances in ADTKD.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe